Mount Sinai Researchers present findings on treatments for prostate and breast cancer

October 18, 2005

Researchers from the Department of Radiation Oncology and the Milton and Caroll Petrie Department of Urology at Mount Sinai School of Medicine are presenting findings from ten studies of prostate and breast cancer treatments at the 47th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), October 16-20, 2005, in Denver, Colorado.

The research results being detailed:
-end-


The Mount Sinai Hospital / Mount Sinai School of Medicine

Related Brachytherapy Articles from Brightsurf:

Outcomes of salvage low dose RT brachytherapy after EBRT for prostate cancer
Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR) prostate brachytherapy (BT) following local recurrence (LR) after external beam radiotherapy (EBRT) for patients with low-to-intermediate risk prostate cancer reported late Grade 3 gastrointestinal and genitourinary adverse events (AEs) occurring in 14% of trial participants.

Brachytherapy proves effective in treating skin cancer
The use of high-dose-rate brachytherapy to treat elderly patients with common skin cancers offers excellent cure rates and cosmetic outcomes, according to a new study.

Aesthetics of skin cancer therapy may vary by treatment type
In a meta-analysis of 58 studies, a study led by Penn State compared four types of skin cancer treatments and found that while all four had similar recurrence rates a year after treatment, a form of radiation called brachytherapy and a type of surgery called Mohs micrographic surgery had better cosmetic results.

Single dose of targeted radiotherapy is safe and effective for prostate cancer
A single high dose of radiation that can be delivered directly to the tumor within a few minutes is a safe and effective technique for treating men with low-risk prostate cancer, according to a study presented at the ESTRO 38 conference.

Benefit of LDR brachytherapy in patients with early-stage prostate cancer is still unclear
Even eleven years after the first benefit assessment, the evidence base remains inadequate.

PROs indicate brachytherapy alone is the superior treatment
Patient-Reported Outcomes (PROs) from the NRG Oncology trial RTOG 0232 comparing a combined treatment of external beam therapy and brachytherapy (EBT+B) to transperineal interstitial permanent brachytherapy (B) alone indicate a significantly different clinician and patient-reported late toxicity profile between arms despite similarities in progression-free survival results.

Brachytherapy for cervical cancer does not increase the risk of ureteral stricture
New research presented at the ESTRO 37 conference from two large international trials, shows that intracavitary and interstitial brachytherapy is safe and does not increase the risk of ureteral stricture in cervical cancer patients.

VCU scientists seek to perfect calculations for comparing cervical cancer radiation doses
Research from VCU Massey Cancer Center has found that one of the standard practices for comparing cervical cancer radiation therapy treatments may be misleading, and the use of an alternative mathematical formula could be used to more effectively predict and potentially improve outcomes for patients.

A gold-standard cancer treatment is in decline, and money may be why
Offering brachytherapy for locally advanced cervical cancer ends up costing hospitals money, potentially explaining its declining use even though it's considered the most effective treatment.

Cleveland Clinic leads development of new guidelines for radiation in breast cancer
Cleveland Clinic researcher Chirag Shah, M.D., led the development of updated guidelines for the appropriate and safe utilization of accelerated partial-breast irradiation (APBI).

Read More: Brachytherapy News and Brachytherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.